Docetaxel (Taxotere™), a novel taxoid, in the treatment of advanced colorectal carcinoma: An EORTC Early Clinical Trials Group Study
Date
1994Author
Sternberg, Cora N.Huinink, W. W. Ten Bokkel
Smyth, J. F.
Bruntsch, V.
Dirix, L. Y.

Franklin, H. R.
Wanders, S.
Bail, N. Le
Kaye, Stanley B.
Source
British journal of cancerVolume
70Issue
2Pages
376-379Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were treated with docetaxel 100 mg m-2 every 3 weeks as a 1 h infusion without routine premedication. Thirty-nine patients were eligible: 23 males and 16 females. Median age was 60 years (range 41-75) and WHO performance status 1 (0-2). Prior adjuvant chemotherapy was performed in four patients and prior radiotherapy in nine patients. Bidimensionally measurable disease sites included: Liver in 26 patients, lymph nodes and abdominal/peritoneal masses in 13, lung/mediastinal masses in ten and subcutaneous nodes in four. The median number of cycles given was 2 (range 1-15). Thirty-three patients were evaluable for response. One patient (3%) achieved a complete response and two (6%) (95% confidence limits 0-14%) a partial response. Side-effects were similar to those observed in other studies. Docetaxel, given at this dosage and schedule, has minimal activity in the treatment of colorectal carcinoma. © Macmillan Press Ltd., 1994.